These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33575481)

  • 1. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
    Imbimbo BP; Lucca U; Watling M
    Neurol Genet; 2021 Feb; 7(1):e535. PubMed ID: 33575481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
    Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Wang G; Li Y; Xiong C; McDade E; Clifford DB; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Libre-Guerra JJ; McCullough A; Joseph-Mathurin N; Chen CD; Mummery C; Wendelberger BA; Gauthier S; Masellis M; Holdridge KC; Yaari R; Chatterjee S; Sims J; Delmar P; Kerchner GA; Bittner T; Hofmann C; Bateman RJ;
    Alzheimers Dement (Amst); 2022; 14(1):e12367. PubMed ID: 36348972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.
    Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S
    Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
    Bateman RJ; Benzinger TL; Berry S; Clifford DB; Duggan C; Fagan AM; Fanning K; Farlow MR; Hassenstab J; McDade EM; Mills S; Paumier K; Quintana M; Salloway SP; Santacruz A; Schneider LS; Wang G; Xiong C;
    Alzheimers Dement; 2017 Jan; 13(1):8-19. PubMed ID: 27583651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
    Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
    Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Salloway S; Farlow M; McDade E; Clifford DB; Wang G; Llibre-Guerra JJ; Hitchcock JM; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Cruchaga C; Goate AA; Perrin RJ; Xiong C; Li Y; Morris JC; Snider BJ; Mummery C; Surti GM; Hannequin D; Wallon D; Berman SB; Lah JJ; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sánchez-Valle R; Brooks WS; Gauthier S; Galasko DR; Masters CL; Brosch JR; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Jack CR; Koeppe R; Snyder PJ; Aisen PS; Thomas RG; Berry SM; Wendelberger BA; Andersen SW; Holdridge KC; Mintun MA; Yaari R; Sims JR; Baudler M; Delmar P; Doody RS; Fontoura P; Giacobino C; Kerchner GA; Bateman RJ;
    Nat Med; 2021 Jul; 27(7):1187-1196. PubMed ID: 34155411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
    Levin J; Vöglein J; Quiroz YT; Bateman RJ; Ghisays V; Lopera F; McDade E; Reiman E; Tariot PN; Morris JC
    Alzheimers Dement; 2022 Dec; 18(12):2687-2698. PubMed ID: 35212149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical
    Tariot PN; Lopera F; Langbaum JB; Thomas RG; Hendrix S; Schneider LS; Rios-Romenets S; Giraldo M; Acosta N; Tobon C; Ramos C; Espinosa A; Cho W; Ward M; Clayton D; Friesenhahn M; Mackey H; Honigberg L; Sanabria Bohorquez S; Chen K; Walsh T; Langlois C; Reiman EM;
    Alzheimers Dement (N Y); 2018; 4():150-160. PubMed ID: 29955659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
    Mills SM; Mallmann J; Santacruz AM; Fuqua A; Carril M; Aisen PS; Althage MC; Belyew S; Benzinger TL; Brooks WS; Buckles VD; Cairns NJ; Clifford D; Danek A; Fagan AM; Farlow M; Fox N; Ghetti B; Goate AM; Heinrichs D; Hornbeck R; Jack C; Jucker M; Klunk WE; Marcus DS; Martins RN; Masters CM; Mayeux R; McDade E; Morris JC; Oliver A; Ringman JM; Rossor MN; Salloway S; Schofield PR; Snider J; Snyder P; Sperling RA; Stewart C; Thomas RG; Xiong C; Bateman RJ
    Rev Neurol (Paris); 2013 Oct; 169(10):737-43. PubMed ID: 24016464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Tang M; Ryman DC; McDade E; Jasielec MS; Buckles VD; Cairns NJ; Fagan AM; Goate A; Marcus DS; Xiong C; Allegri RF; Chhatwal JP; Danek A; Farlow MR; Fox NC; Ghetti B; Graff-Radford NR; Laske C; Martins RN; Masters CL; Mayeux RP; Ringman JM; Rossor MN; Salloway SP; Schofield PR; Morris JC; Bateman RJ;
    Lancet Neurol; 2016 Dec; 15(13):1317-1325. PubMed ID: 27777020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).
    Cairns NJ; Perrin RJ; Franklin EE; Carter D; Vincent B; Xie M; Bateman RJ; Benzinger T; Friedrichsen K; Brooks WS; Halliday GM; McLean C; Ghetti B; Morris JC; ;
    Neuropathology; 2015 Aug; 35(4):390-400. PubMed ID: 25964057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.
    Morris JC; Aisen PS; Bateman RJ; Benzinger TL; Cairns NJ; Fagan AM; Ghetti B; Goate AM; Holtzman DM; Klunk WE; McDade E; Marcus DS; Martins RN; Masters CL; Mayeux R; Oliver A; Quaid K; Ringman JM; Rossor MN; Salloway S; Schofield PR; Selsor NJ; Sperling RA; Weiner MW; Xiong C; Moulder KL; Buckles VD
    Clin Investig (Lond); 2012 Oct; 2(10):975-984. PubMed ID: 23139856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.
    Schindler SE; Fagan AM
    Front Neurol; 2015; 6():142. PubMed ID: 26175713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.